Literature DB >> 23474803

Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation.

E Rettinger, H Bonig, S Wehner, G Lucchini, A Willasch, A Jarisch, J Soerensen, R Esser, C Rossig, T Klingebiel, P Bader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23474803     DOI： 10.1038/bmt.2013.19

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.

Authors:  Weng-Chee Chan; Yeh-Ching Linn
Journal:  Cytotechnology       Date:  2014-12-07       Impact factor: 2.058

2.  More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.

Authors:  Peter Bader; Emilia Salzmann-Manrique; Adriana Balduzzi; Jean-Hugues Dalle; Ann E Woolfrey; Merav Bar; Michael R Verneris; Michael J Borowitz; Nirali N Shah; Nathan Gossai; Peter J Shaw; Allen R Chen; Kirk R Schultz; Hermann Kreyenberg; Lucia Di Maio; Gianni Cazzaniga; Cornelia Eckert; Vincent H J van der Velden; Rosemary Sutton; Arjan Lankester; Christina Peters; Thomas E Klingebiel; Andre M Willasch; Stephan A Grupp; Michael A Pulsipher
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

4.  Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.

Authors:  Melanie Bremm; Lisa-Marie Pfeffermann; Claudia Cappel; Verena Katzki; Stephanie Erben; Sibille Betz; Andrea Quaiser; Michael Merker; Halvard Bonig; Michael Schmidt; Thomas Klingebiel; Peter Bader; Sabine Huenecke; Eva Rettinger
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

5.  Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience.

Authors:  Michael Merker; Michael Torsten Meister; Annekathrin Heinze; Andrea Jarisch; Jan Sörensen; Sabine Huenecke; Melanie Bremm; Claudia Cappel; Thomas Klingebiel; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2019-10-22

6.  Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives.

Authors:  Chiara F Magnani; Sarah Tettamanti; Francesca Maltese; Nice Turazzi; Andrea Biondi; Ettore Biagi
Journal:  Front Oncol       Date:  2013-04-30       Impact factor: 6.244

7.  SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.

Authors:  Eva Rettinger; Andreas Glatthaar; Behnaz Ahangarian Abhari; Sarah Oelsner; Verena Pfirrmann; Sabine Huenecke; Selim Kuçi; Hermann Kreyenberg; Andre M Willasch; Thomas Klingebiel; Simone Fulda; Peter Bader
Journal:  Front Pediatr       Date:  2014-07-18       Impact factor: 3.418

8.  In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.

Authors:  Melanie Bremm; Sabine Huenecke; Olga Zimmermann; Verena Pfirrmann; Andrea Quaiser; Halvard Bonig; Jan Soerensen; Thomas Klingebiel; Eva Rettinger; Peter Bader; Claudia Cappel
Journal:  J Transl Med       Date:  2016-09-13       Impact factor: 5.531

Review 9.  Innovative Clinical Perspectives for CIK Cells in Cancer Patients.

Authors:  Martino Introna; Fabio Correnti
Journal:  Int J Mol Sci       Date:  2018-01-25       Impact factor: 5.923

10.  Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Authors:  Michael Merker; Verena Pfirrmann; Sarah Oelsner; Simone Fulda; Thomas Klingebiel; Winfried S Wels; Peter Bader; Eva Rettinger
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.